Literature DB >> 9693308

Downgraded non-Hodgkin's lymphoma in the neck occurring as a secondary malignancy.

Y Ogata1, M Setoguchi, T Tahara, M Takahashi.   

Abstract

While the histologic progression from low-grade non-Hodgkin's lymphoma (NHL) to intermediate- or high-grade NHL has been well documented, a rare phenomenon called downgrading in which the histologic conversion of a low-grade NHL occurs after treatment for intermediate- or high-grade NHL has recently been recognized. We report the clinical, immunologic, and genetic features of a patient with a diffuse NHL (intermediate grade) who initially achieved complete remission by both chemotherapy and radiation therapy and then presented with a follicular NHL (low grade) 14 years later. The immunohistochemical study of the lymphoma cells showed B lymphocytes in biopsied lymph nodes at both the initial and the second diagnosis. However, a polymerase chain reaction (PCR) analysis for the immunoglobulin gene rearrangement indicated that the clone of the initial intermediate-grade NHL showed monoclonal cell population, and was distinct from that of the second downgraded form. Given the PCR results and the clinical features, we suggest that a follicular NHL can occur as a secondary malignancy following combined therapy for a diffuse NHL.

Entities:  

Mesh:

Year:  1998        PMID: 9693308     DOI: 10.1159/000027613

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  2 in total

1.  Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma--De Novo Occurrence or Transformation.

Authors:  Smeeta Gajendra; Bhawna Jha; Shalini Goel; Tushar Sahni; Pranav Dorwal; Ritesh Sachdev
Journal:  Turk J Haematol       Date:  2015-09-28       Impact factor: 1.831

2.  Comment: In Response to "Downgraded Lymphoma: B-Chronic Lymphocytic Leukemia in a Known Case of Diffuse Large B-Cell Lymphoma - De Novo Occurrence or Transformation".

Authors:  Burak Uz; Kadir Acar
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.